Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Europska Unija - hrvatski - EMA (European Medicines Agency)

teva b.v. - xinafoate сальметерол, flutikazon propionat - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Europska Unija - hrvatski - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - plućna bolest, kronična opstruktivna - lijekovi za opstruktivne plućne bolesti dišnih putova, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - tezepelumab - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imuni serumi i homologna, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.